The role of 18FDG–PET imaging in VEXAS syndrome: a multicentric case series and a systematic review of the literature
-
Published:2024-09-09
Issue:
Volume:
Page:
-
ISSN:1828-0447
-
Container-title:Internal and Emergency Medicine
-
language:en
-
Short-container-title:Intern Emerg Med
Author:
Bixio RiccardoORCID, Bindoli SaraORCID, Morciano AndreaORCID, Padoan RobertoORCID, Aldegheri FedericoORCID, Mastropaolo FrancescaORCID, Bertoldo EugeniaORCID, Rotta DeniseORCID, Appoloni MatteoORCID, Orsolini GiovanniORCID, Gatti DavideORCID, Adami GiovanniORCID, Viapiana OmbrettaORCID, Rossini MaurizioORCID, Sfriso PaoloORCID, Fassio AngeloORCID
Abstract
AbstractVEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic) syndrome is characterized by heterogeneous clinical manifestations. Due to the inflammatory nature of this condition, 18-FDG–PET (18-fluorodeoxyglucose–positron emission tomography) might be used to diagnose and monitor the disease. However, no data are available about the most common findings of PET imaging in this disease. For this reason, we summarised all the available reports of patients with VEXAS who underwent at least one PET scan and described 8 additional patients’ PET from our centres. Overall, we described 35 patients’ PET findings. All patients were male, with a median age of 70 years. The most frequent hypermetabolic sites on PET scans were the bone marrow (77.1%), lymph nodes (35.3%), lungs (28.6%), spleen and large vessels (22.9%), and cartilage (20%). Six patients underwent a PET scan 2.7 ± 1.5 years before VEXAS diagnosis, showing nonspecific uptake in the bone marrow. Four patients had a follow-up PET scan, showing a decrease or a disappearance of the previously identified hypermetabolic areas. In conclusion, although no specific uptake site has been found for VEXAS syndrome, PET imaging could help detect inflammatory foci that are not clinically evident. In addition, high metabolic activity in bone marrow might precede the clinical onset of the disease, shedding light on the pathogenesis of VEXAS.
Funder
Università degli Studi di Verona
Publisher
Springer Science and Business Media LLC
Reference60 articles.
1. Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, Balanda N, Ross DL, Ospina Cardona D, Wu Z, Patel B, Manthiram K, Groarke EM, Gutierrez-Rodrigues F, Hoffmann P, Rosenzweig S, Nakabo S, Dillon LW, Hourigan CS, Tsai WL, Gupta S, Carmona-Rivera C, Asmar AJ, Xu L, Oda H, Goodspeed W, Barron KS, Nehrebecky M, Jones A, Laird RS, Deuitch N, Rowczenio D, Rominger E, Wells KV, Lee C-CR, Wang W, Trick M, Mullikin J, Wigerblad G, Brooks S, Dell’Orso S, Deng Z, Chae JJ, Dulau-Florea A, Malicdan MCV, Novacic D, Colbert RA, Kaplan MJ, Gadina M, Savic S, Lachmann HJ, Abu-Asab M, Solomon BD, Retterer K, Gahl WA, Burgess SM, Aksentijevich I, Young NS, Calvo KR, Werner A, Kastner DL, Grayson PC (2020) Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 383:2628–2638. https://doi.org/10.1056/NEJMoa2026834 2. Malcovati L (2023) VEXAS: walking on the edge of malignancy. Blood 142:214–215. https://doi.org/10.1182/blood.2023020772 3. Gutierrez-Rodrigues F, Kusne Y, Fernandez J, Lasho T, Shalhoub R, Ma X, Alessi H, Finke C, Koster MJ, Mangaonkar A, Warrington KJ, Begna K, Xie Z, Ombrello AK, Viswanatha D, Ferrada M, Wilson L, Go R, Kourelis T, Reichard K, Olteanu H, Darden I, Hironaka D, Alemu L, Kajigaya S, Rosenzweig S, Calado RT, Groarke EM, Kastner DL, Calvo KR, Wu CO, Grayson PC, Young NS, Beck DB, Patel BA, Patnaik MM (2023) Spectrum of clonal hematopoiesis in VEXAS syndrome. Blood 142:244–259. https://doi.org/10.1182/blood.2022018774 4. Boyadzhieva Z, Ruffer N, Kötter I, Krusche M (2023) How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies. Rheumatology. https://doi.org/10.1093/rheumatology/kead240 5. Heiblig M, Ferrada MA, Koster MJ, Barba T, Gerfaud-Valentin M, Mékinian A, Coelho H, Fossard G, Barraco F, Galicier L, Bienvenu B, Hirsch P, Vial G, Boutin AB, Galland J, Le Guenno G, Bigot A, Warrington KJ, Kermani TA, Grayson PC, Patel BA, Beck DB, Jamilloux Y, Fenaux P, Sujobert P (2022) Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood 140:927–931. https://doi.org/10.1182/blood.2022016642
|
|